Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Experimental Oncology
  • Published:

Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67

Abstract

Thirty-one cervical biopsies of invasive carcinoma have been studied by immunohistochemical means using the monoclonal antibody Ki67 to determine tumour cell proliferation rates. A wide range (10-50%) in the extent of Ki67 staining (expressed as the percentage of labelled tumour cells) was observed indicating considerable variation on tumour growth rates. There was no significant relationship between the percentage of positive cells and conventional histological parameters such as cell type or tumour differentiation. Immunostaining with monoclonal antibody Ki67 therefore provides a new approach to the assessment of cervical tumour biopsies which will require long term clinical follow-up to establish its prognostic significance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, D., Cole, D., Gatter, K. et al. Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67. Br J Cancer 57, 178–181 (1988). https://doi.org/10.1038/bjc.1988.37

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1988.37

This article is cited by

Search

Quick links